Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of “Hold” by Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have earned an average rating of “Hold” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.3333.

CNTA has been the subject of several research reports. Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $35.00 to $42.00 in a research report on Monday, April 20th. B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Finally, Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 309,112 shares of company stock valued at $8,424,535. 4.09% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its stake in shares of Centessa Pharmaceuticals by 34.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 12.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock worth $282,156,000 after purchasing an additional 1,246,741 shares during the period. Farallon Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 24.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock worth $134,480,000 after purchasing an additional 1,045,750 shares during the period. Perceptive Advisors LLC grew its stake in shares of Centessa Pharmaceuticals by 80.2% during the 1st quarter. Perceptive Advisors LLC now owns 5,258,903 shares of the company’s stock worth $208,884,000 after purchasing an additional 2,341,269 shares during the period. Finally, Siren L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 24.8% during the 4th quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after purchasing an additional 800,000 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Down 0.5%

CNTA stock opened at $39.62 on Friday. The company has a fifty day moving average price of $38.98 and a 200 day moving average price of $30.46. Centessa Pharmaceuticals has a 12 month low of $11.55 and a 12 month high of $40.26. The company has a market cap of $5.91 billion, a price-to-earnings ratio of -22.13 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Sell-side analysts expect that Centessa Pharmaceuticals will post -1.65 earnings per share for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.